checkAd

     149  0 Kommentare Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing

    Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in …

    Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test

    STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in PCR-based DNA technologies, today announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC (ADCL), will utilize the GenXys Health Care Systems (GenXys) suite of clinical decision support software for interpretation and reporting of ADCL's New York State Department of Health-approved TR8 pharmacogenomic (TR8 PGx) test. The partnership is designed to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual's genetic factors to potential responses to prescription drugs.

    Dr. James Hayward, president and CEO of Applied DNA, stated, "We at ADCL believe that PGx-enabled precision prescribing provides numerous benefits to patients, payors, and healthcare as a whole - all empowered by a simple buccal swab. A single test provides a lifetime of guidance (video) and can provide a significant return on investment, especially for large healthcare networks. To realize these benefits, healthcare providers must have easy-to-understand information about potential drug-gene interactions identified by PGx testing. We believe that GenXys offers best-in-class PGx clinical integration services, and we are excited to partner with GenXys as our go-to-market partner for our TR8 PGx test."

    Applied DNA's TR8 PGx assay simultaneously interrogates 120 genetic variants across more than 30 genes that have been shown to affect the rate with which the body absorbs, activates, distributes, and metabolizes drugs, which can, in turn, impact the efficacy and safety of medications. The genetic variations targeted by TR8 PGx are relevant to a broad range of medicines, including cardiac, pain management, cancer, and psychiatric drugs.

    The genetic variants identified by the TR8 PGx test will be processed by the GenXys clinical decision support software to identify potentially actionable drug-gene interactions that can help guide precision prescribing decisions by a healthcare provider. Numerous studies have shown that PGx-guided precision prescribing can improve therapeutic efficacy and patient compliance and diminish adverse reactions and rehospitalizations.

    Seite 1 von 3



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    Verfasst von Accesswire
    Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY / ACCESSWIRE / June 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a global leader in …